WASHINGTON, D.C. – Today, Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, led a hearing titled Examining Biosecurity at the Intersection of AI and Biology.
“As a physician, I must acknowledge the extraordinary promise that AI-enabled biotechnology holds for patient care. AI is accelerating drug discovery, improving protein modeling, and enabling the development of therapies with unprecedented precision,” said Chairman Joyce. “The Trump Administration has taken steps to keep up with such advancements, but the federal government must continue to carefully assess whether our current safeguards and reporting systems are adequate in an era of rapidly advancing AI technology.”
Watch the full hearing here
Below are key excerpts from today’s hearing:
Congressman Dan Crenshaw (TX-02): “We've talked a lot about how AI can be used for all sorts of scary things. What about the good parts? What about assisting industry leaders and researchers in identifying biosecurity risks? In other words, you know, how can we use AI for good?” Mr. McKnight: “Thank you for the question. This builds on the conversation we were having about select agent lists and then the new incredible diversity of threats. The same way the biodesign tools that we're talking about can create new proteins and give lessons on how to create new medicines, those same tools can be turned around. [...] They can be turned around to automate the process of interpreting a sample that you're looking at, and then the development roadmap that is funded through these programs is to use AI to go from sequence detection to what the function is.”
Congressman Russ Fulcher (ID-01): “In an attempt to try to close the door on this, President Trump had the executive order back in May. And looking at the gene synthesis, in the section of the President's EO of the gene synthesis section, can you say what specific parts of that order are actually going to stop these threats, or have the best chance of stopping these threats? Can they stop [those] threats if implemented? And, just a follow up, what else should we in Congress be doing about this?” Dr. Pannu: “Thank you for the question. Overall, I'm glad that you mentioned the executive order from May; I think that's an important initiative. There are a couple of things in that I would want to highlight: the gene synthesis provisions do call on Congress to proceed with a legislative effort to make gene synthesis screening mandatory across the U.S., that's something that Congress could advance. The other provisions on clearly defining what is dangerous gain of function research, those policies have yet to be released from the Office of Science and Technology Policy, so Congress could ask for an update as to those, and where they currently stand.”
Congresswoman Diana Harshbarger (TN-01): “Are there early warning indicators—whether they're digital, biological or supply chain—that could help identify AI-enabled biological misuse? Because you talked about that digital to physical barrier.” Mr. McKnight: “Yes, one of the key capabilities that we work on is when you take a sample with Biothreat Radar from an airport, or from a community, or from a threat location, you bring it, you do DNA sequencing with it. […] We have a set of tools that we are constantly developing with cutting edge machine learning AI to analyze that DNA to tell you what’s in it, what different types of pathogens, are there new things that you haven’t seen? And one of the very specific tools that we work on that was developed in conjunction with IARPA […] is a tool that actually looks and algorithmically scores to identify if something has been genetically engineered or not.”
###